ArticleEClinicalMedicine2026
Long-term real-world outcomes following preoperative radiotherapy and conservative surgery for trunk and extremity soft tissue sarcomas: a retrospective cohort study.
Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Radiotherapy (RT) combined with surgery is standard of care for most soft tissue sarcoma (STS) of the extremity and trunk. Preoperative RT is often preferred because it enables a lower radiation dose and is associated with more favorable late toxicity profiles. We report real-world, long-term oncological, toxicity, and functional outcomes of patients treated with preoperative RT at a sarcoma reference center. Methods: We did a retrospective analysis of data from our prospectively maintained database (data collected from April 1989 to November 2020) from a single sarcoma center in Canada. We included patients with histologically confirmed STS of extremity or trunk. Eligible patients received preoperative RT with either 2D/3D-Conformal Radiation Therapy (3D-CRT) or Intensity Modulated Radiation Therapy (IMRT), followed by surgery 4-6 weeks later. Local and oncological outcomes were assessed. Long-term toxicities were graded using the RTOG late toxicity scoring criteria. The Musculoskeletal Tumor Society Rating Scale (MSTS) and Toronto Extremity Salvage Score (TESS) evaluated functional outcomes. Further study endpoints included the occurrence of distant metastases (DM) and overall survival (OS), stratified by histology. Findings: Among 1027 patients (370 3D-CRT, 657 IMRT), the median follow-up was 5.9 years (range: 0.5-24.6 years). Major wound complications occurred in 28% with 3D-CRT and in 21% with IMRT (p = 0.09). The 5-year cumulative rates of local recurrence (LR) and distant metastasis were 5.2% vs. 5.4% and 25.5% vs. 25.6%, with a 5-year overall survival of 79.3%. None of these outcomes differed significantly between 3D-CRT and IMRT. Grade ≥2 late toxicity occurred in 25% (30% in 3D-CRT and 22% in IMRT), including fibrosis (17%), skin toxicity (9%), joint stiffness (6%), and edema (9%). IMRT was associated with significantly lower rates of grade ≥2 skin toxicity (OR 0.28), subcutaneous fibrosis (OR 0.55), and joint stiffness (OR 0.49) compared to 3D-CRT. Functional outcomes were comparable between IMRT and 3D-CRT. Patients with grade ≥2 toxicities had lower functional scores (p < 0.001). Interpretation: In this large cohort with mature follow-up, long-term local control and function were excellent with low rates of high-grade toxicity. Modern RT techniques were associated with less late toxicity without compromising local control, but acute wound complications and distant metastases remain ongoing challenges. Funding: None.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.